vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Hilltop Holdings Inc. (HTH). Click either name above to swap in a different company.
Hilltop Holdings Inc. is the larger business by last-quarter revenue ($300.5M vs $183.1M, roughly 1.6× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs 13.0%, a 0.4% gap on every dollar of revenue. Over the past eight quarters, Amphastar Pharmaceuticals, Inc.'s revenue compounded faster (3.2% CAGR vs 0.6%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Hilltop Holdings Inc. is a financial holding company based in Dallas, Texas. It offers financial products and banking services through three primary subsidiaries: PlainsCapital Bank, PrimeLending, and HilltopSecurities.
AMPH vs HTH — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $300.5M |
| Net Profit | $24.4M | $39.0M |
| Gross Margin | 46.8% | — |
| Operating Margin | 19.4% | — |
| Net Margin | 13.3% | 13.0% |
| Revenue YoY | -1.8% | — |
| Net Profit YoY | -35.7% | -12.4% |
| EPS (diluted) | $0.51 | $0.64 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $300.5M | ||
| Q4 25 | $183.1M | $329.9M | ||
| Q3 25 | $191.8M | $330.2M | ||
| Q2 25 | $174.4M | $303.3M | ||
| Q1 25 | $170.5M | $318.5M | ||
| Q4 24 | $186.5M | $301.1M | ||
| Q3 24 | $191.2M | $305.5M | ||
| Q2 24 | $182.4M | $297.0M |
| Q1 26 | — | $39.0M | ||
| Q4 25 | $24.4M | $41.6M | ||
| Q3 25 | $17.4M | $45.8M | ||
| Q2 25 | $31.0M | $36.1M | ||
| Q1 25 | $25.3M | $42.1M | ||
| Q4 24 | $38.0M | $35.5M | ||
| Q3 24 | $40.4M | $29.7M | ||
| Q2 24 | $37.9M | $20.3M |
| Q1 26 | — | — | ||
| Q4 25 | 46.8% | — | ||
| Q3 25 | 51.4% | — | ||
| Q2 25 | 49.6% | — | ||
| Q1 25 | 50.0% | — | ||
| Q4 24 | 46.5% | — | ||
| Q3 24 | 53.3% | — | ||
| Q2 24 | 52.2% | — |
| Q1 26 | — | — | ||
| Q4 25 | 19.4% | 16.1% | ||
| Q3 25 | 13.2% | 18.4% | ||
| Q2 25 | 24.2% | 16.3% | ||
| Q1 25 | 21.9% | 18.1% | ||
| Q4 24 | 24.2% | 14.7% | ||
| Q3 24 | 29.8% | 13.9% | ||
| Q2 24 | 30.3% | 10.0% |
| Q1 26 | — | 13.0% | ||
| Q4 25 | 13.3% | 12.6% | ||
| Q3 25 | 9.0% | 13.9% | ||
| Q2 25 | 17.8% | 11.9% | ||
| Q1 25 | 14.8% | 13.2% | ||
| Q4 24 | 20.4% | 11.8% | ||
| Q3 24 | 21.1% | 9.7% | ||
| Q2 24 | 20.8% | 6.8% |
| Q1 26 | — | $0.64 | ||
| Q4 25 | $0.51 | $0.68 | ||
| Q3 25 | $0.37 | $0.74 | ||
| Q2 25 | $0.64 | $0.57 | ||
| Q1 25 | $0.51 | $0.65 | ||
| Q4 24 | $0.74 | $0.55 | ||
| Q3 24 | $0.78 | $0.46 | ||
| Q2 24 | $0.73 | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | — |
| Total DebtLower is stronger | $608.7M | $990.8M |
| Stockholders' EquityBook value | $788.8M | $2.2B |
| Total Assets | $1.6B | $15.7B |
| Debt / EquityLower = less leverage | 0.77× | 0.46× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.8M | — | ||
| Q3 25 | $276.2M | — | ||
| Q2 25 | $231.8M | — | ||
| Q1 25 | $236.9M | — | ||
| Q4 24 | $221.6M | — | ||
| Q3 24 | $250.5M | — | ||
| Q2 24 | $217.8M | — |
| Q1 26 | — | $990.8M | ||
| Q4 25 | $608.7M | — | ||
| Q3 25 | $608.6M | — | ||
| Q2 25 | $607.7M | — | ||
| Q1 25 | $603.9M | — | ||
| Q4 24 | $601.6M | — | ||
| Q3 24 | $596.4M | — | ||
| Q2 24 | $586.9M | — |
| Q1 26 | — | $2.2B | ||
| Q4 25 | $788.8M | $2.2B | ||
| Q3 25 | $776.7M | $2.2B | ||
| Q2 25 | $757.5M | $2.2B | ||
| Q1 25 | $751.3M | $2.2B | ||
| Q4 24 | $732.3M | $2.2B | ||
| Q3 24 | $727.7M | $2.2B | ||
| Q2 24 | $713.3M | $2.1B |
| Q1 26 | — | $15.7B | ||
| Q4 25 | $1.6B | $15.8B | ||
| Q3 25 | $1.7B | $15.6B | ||
| Q2 25 | $1.6B | $15.4B | ||
| Q1 25 | $1.6B | $15.8B | ||
| Q4 24 | $1.6B | $16.3B | ||
| Q3 24 | $1.5B | $15.9B | ||
| Q2 24 | $1.5B | $15.6B |
| Q1 26 | — | 0.46× | ||
| Q4 25 | 0.77× | — | ||
| Q3 25 | 0.78× | — | ||
| Q2 25 | 0.80× | — | ||
| Q1 25 | 0.80× | — | ||
| Q4 24 | 0.82× | — | ||
| Q3 24 | 0.82× | — | ||
| Q2 24 | 0.82× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | — |
| Free Cash FlowOCF − Capex | $24.6M | — |
| FCF MarginFCF / Revenue | 13.4% | — |
| Capex IntensityCapex / Revenue | 4.5% | — |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $32.9M | $-38.7M | ||
| Q3 25 | $52.6M | $273.0M | ||
| Q2 25 | $35.6M | $-234.6M | ||
| Q1 25 | $35.1M | $5.8M | ||
| Q4 24 | $29.0M | $273.9M | ||
| Q3 24 | $60.0M | $515.6M | ||
| Q2 24 | $69.1M | $-435.3M |
| Q1 26 | — | — | ||
| Q4 25 | $24.6M | $-55.5M | ||
| Q3 25 | $47.2M | $271.0M | ||
| Q2 25 | $25.0M | $-234.6M | ||
| Q1 25 | $24.4M | $5.0M | ||
| Q4 24 | $16.6M | $266.8M | ||
| Q3 24 | $46.2M | $513.8M | ||
| Q2 24 | $63.1M | $-437.3M |
| Q1 26 | — | — | ||
| Q4 25 | 13.4% | -16.8% | ||
| Q3 25 | 24.6% | 82.1% | ||
| Q2 25 | 14.3% | -77.4% | ||
| Q1 25 | 14.3% | 1.6% | ||
| Q4 24 | 8.9% | 88.6% | ||
| Q3 24 | 24.1% | 168.2% | ||
| Q2 24 | 34.6% | -147.2% |
| Q1 26 | — | — | ||
| Q4 25 | 4.5% | 5.1% | ||
| Q3 25 | 2.8% | 0.6% | ||
| Q2 25 | 6.1% | 0.0% | ||
| Q1 25 | 6.3% | 0.3% | ||
| Q4 24 | 6.7% | 2.4% | ||
| Q3 24 | 7.2% | 0.6% | ||
| Q2 24 | 3.3% | 0.7% |
| Q1 26 | — | — | ||
| Q4 25 | 1.35× | -0.93× | ||
| Q3 25 | 3.03× | 5.96× | ||
| Q2 25 | 1.15× | -6.50× | ||
| Q1 25 | 1.39× | 0.14× | ||
| Q4 24 | 0.76× | 7.71× | ||
| Q3 24 | 1.48× | 17.36× | ||
| Q2 24 | 1.82× | -21.41× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
HTH
| Noninterest Income | $188.4M | 63% |
| Net Interest Income | $112.1M | 37% |
